These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 16755647)

  • 1. Patient empowerment: rofecoxib revisited.
    Tannenbaum H
    J Rheumatol; 2006 Jun; 33(6):1033-5. PubMed ID: 16755647
    [No Abstract]   [Full Text] [Related]  

  • 2. Cardiovascular complications of COX2 selective inhibitors cause considerable concern.
    Hedner T; Himmelmann A
    Blood Press; 2004; 13(5):260-1. PubMed ID: 15545147
    [No Abstract]   [Full Text] [Related]  

  • 3. Increased risk of cardiovascular events with coxibs and NSAIDs.
    Scott DG; Watts RA
    Lancet; 2005 Apr 30-May 6; 365(9470):1537. PubMed ID: 15866299
    [No Abstract]   [Full Text] [Related]  

  • 4. COX-2 inhibitors and hypercoagulability.
    Farkouh ME
    Clin Adv Hematol Oncol; 2005 Jan; 3(1):35-6. PubMed ID: 16166966
    [No Abstract]   [Full Text] [Related]  

  • 5. Rofecoxib (Vioxx) withdrawal: do product monographs adequately inform physicians?
    Can Fam Physician; 2005 Feb; 51(2):212-3. PubMed ID: 15751564
    [No Abstract]   [Full Text] [Related]  

  • 6. Intracranial hypertension induced by rofecoxib.
    Jacob S; Rajabally YA
    Headache; 2005 Jan; 45(1):75-6. PubMed ID: 15663617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rofecoxib for osteoarthritis and pain.
    Med Lett Drugs Ther; 1999 Jul; 41(1056):59-61. PubMed ID: 10436769
    [No Abstract]   [Full Text] [Related]  

  • 8. [The rise and fall of Vioxx: society, values and their choice].
    Caspi D
    Harefuah; 2004 Nov; 143(11):770-1. PubMed ID: 15603261
    [No Abstract]   [Full Text] [Related]  

  • 9. A tale of two coxibs.
    Hegmann T
    JAAPA; 2005 Mar; 18(3):14, 17. PubMed ID: 15789666
    [No Abstract]   [Full Text] [Related]  

  • 10. [VIOXX written off--and what next? COX-2 inhibitors and cardiovascular diseases].
    Jerie P
    Cas Lek Cesk; 2005; 144(1):4. PubMed ID: 15789774
    [No Abstract]   [Full Text] [Related]  

  • 11. [Severe acute cholestatic and cytolytic hepatitis induced by rofecoxib].
    Ouar S; Bellaïche G; Belloc J; Tordjman G; Ley G; Slama JL
    Gastroenterol Clin Biol; 2005 Apr; 29(4):471-2. PubMed ID: 15918218
    [No Abstract]   [Full Text] [Related]  

  • 12. [Really only Vioxx?].
    Heinzl S
    Med Monatsschr Pharm; 2004 Nov; 27(11):361. PubMed ID: 15566229
    [No Abstract]   [Full Text] [Related]  

  • 13. A quantitative evaluation of the regulatory assessment of the benefits and risks of rofecoxib relative to naproxen: an application of the incremental net-benefit framework.
    Lynd LD; Marra CA; Najafzadeh M; Sadatsafavi M
    Pharmacoepidemiol Drug Saf; 2010 Nov; 19(11):1172-80. PubMed ID: 20602338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What happened to the coxibs on the way to the cardiologist?
    Alberts DS; Potter JD; Martinez ME; Hess LM; Stopeck A; Lance P
    Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):555-6. PubMed ID: 15767326
    [No Abstract]   [Full Text] [Related]  

  • 15. Health Canada lukewarm on Vioxx panel findings.
    Murray S
    CMAJ; 2005 Aug; 173(4):350. PubMed ID: 16103502
    [No Abstract]   [Full Text] [Related]  

  • 16. Nephrotoxicity of selective COX-2 inhibitors.
    Woywodt A; Schwarz A; Mengel M; Haller H; Zeidler H; Köhler L
    J Rheumatol; 2001 Sep; 28(9):2133-5. PubMed ID: 11550988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severe upper gastrointestinal bleeding during treatment with rofecoxib for osteoarthritis.
    Caroli A; Monica F
    Am J Gastroenterol; 2001 May; 96(5):1663-5. PubMed ID: 11374736
    [No Abstract]   [Full Text] [Related]  

  • 18. Possible role for human leukocyte antigen haplotype in rofecoxib-associated acute pancreatitis and cholestatic hepatitis.
    Sato K; Yamada E; Uehara Y; Takagi H; Mori M
    Clin Pharmacol Ther; 2006 Nov; 80(5):554-5. PubMed ID: 17112814
    [No Abstract]   [Full Text] [Related]  

  • 19. [Cardiovascular risks of Cox-2-antagonists. Opinion on the marketed name rofecoxib, and its market-withdrawn valdecoxib and the actual therapeutic restrictions].
    Bolten WW; Reiter S;
    Z Rheumatol; 2005 May; 64(4):286-9. PubMed ID: 15909092
    [No Abstract]   [Full Text] [Related]  

  • 20. Balancing risks and benefits in pain medicine: wither Vioxx.
    Gallagher RM
    Pain Med; 2004 Dec; 5(4):329-30. PubMed ID: 15563316
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.